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Polyomaviruses are DNA tumor viruses with small circular genomes encoding only six proteins including three structural capsid proteins.
Despite this simplicity, our understanding of the mechanisms of polyomavirus-mediated tumorigenesis is far from complete. The archetypal
primate polyomavirus, SV40, was isolated more than 40 years ago and has been used extensively as a model system for the study of basic
eukaryotic cellular processes such as DNA replication and transcription. Two human polyomaviruses have been isolated from clinical
samples: JC virus (JCV) and BK virus (BKV). In this review, SV40, JCV, and BKV will be compared based on what is known about their
molecular biology from experiments performed in vitro, in cell culture and in laboratory animals. The association of these viruses with
clinical tumors is discussed along with the possible roles of these polyomaviruses in the etiology of human malignant disease.
D 2004 Elsevier Inc. All rights reserved.Keywords: Polyomaviruses; Human cancer; TumorigenesisIntroduction
Polyomaviruses are a genus of non-enveloped DNA
viruses with icosahedral capsids containing small, circular,
double-stranded DNA genomes. These viruses have been
isolated from humans, monkeys, rodents, and birds. Each
polyomavirus has a limited host range and does not usually
produce productive infections in other species (Cole, 1996;
Imperiale, 2001).
Mouse polyoma virus (Stewart et al., 1958) and simian
vacuolatingvirus 40 (SV40) (Sweet andHilleman, 1960)were
the first polyomaviruses to be discovered.As its name implies,
mouse polyoma virus is able to induce a variety of different
tumors when it is inoculated into newborn mice. These two
archetypal polyomaviruses have been intensively studied
and have provided a model system for the study of basic
eukaryotic cell processes including DNA replication, tran-
scription, malignant transformation, and signal transduction.
In 1971, two human polyomaviruses were discovered.
BK virus was isolated from the urine of a kidney allograft
recipient with chronic pyelonephritis and advanced renal0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: martyn.white@temple.edu (M.K. White).failure (Gardner et al., 1971). JC virus was isolated from the
brain of a patient suffering from progressive multifocal
leukoencephalopathy (Padgett et al., 1971). The designa-
tions JC and BK were derived from the initials of the
patients involved.
Both BK and JC viruses are very similar to SV40 with
respect to size (f5.2 kbp), genome organization, and DNA
sequence. The circular genome of these polyomaviruses
contains two regions of approximately equal size known
as the early and late transcription units. Transcription of
both units is initiated from a common regulatory region at
the origin of DNA replication (ori) with early transcription
proceeding in a counterclockwise direction. Late transcrip-
tion proceeds from ori in the opposite direction and goes
around the genome in a clockwise direction (Cole, 1996;
Imperiale, 2001). The late region encodes the capsid struc-
tural proteins VP1, VP2, and VP3 that are encoded by
alternatively spliced mRNAs derived from the same primary
late transcript and a small regulatory protein known as
Agnoprotein that is discussed below. The early region
encodes the alternatively spliced transforming proteins:
large T antigen (T-Ag) and small t antigen (t-Ag). These
proteins are important in promoting transformation of cells
in culture and oncogenesis in vivo, as discussed below. The
polyomavirus virion consists of a capsid containing VP1,
VP2, and VP3 surrounding a single molecule of supercoiled
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histones, H2A, H2B, H3, and H4, which is often referred to
as the viral minichromosome (Chen et al., 1979; Tan, 1977).
After infection, the viral minichromosome facilitates viral
transcription and contains histone H1.
There are two possible outcomes to infection of a cell by
a polyomavirus. Permissive cells are cells that are able to
support viral DNA replication and the result of polyomavi-
rus entry is a lytic infection with viral amplification.
Nonpermissive cells are cells that do not support viral
DNA replication and the result of viral entry is an abortive
infection or cell transformation (oncogenesis). Two exam-
ples illustrate this distinction. Firstly, when SV40 infects
nonpermissive mouse cells, for example, 3T3 fibroblasts,
species-related differences block viral DNA replication and
cell transformation occurs (Todaro and Green, 1966).
Experiments with cell extract suggest that the species-
related block in SV40 replication is caused by an inability
of the primate virus to use the mouse host DNA polymerase
(Murakami et al., 1986). Secondly, when SV40 infects
permissive monkey kidney cell lines, the virus replicates
and cell lysis occurs.
Most human cells represent a unique intermediate status
with respect to SV40 infection. When SV40 infects human
fibroblasts, DNA replication is only partially effective and
the virus is amplified and cell transformation occurs (dis-
cussed below). Another example of the intermediate status
of human cells with respect to SV40 is afforded by human
lymphoblastoid B-cell lines that grow in culture, yet pro-
duce SV40 at a low level (Dolcetti et al., 2003).
However, in human mesothelial cells, cell-type-specific
differences completely block viral replication, and in this
nonpermissive situation, cells are particularly amenable to
transformation. This may have important implications in
human mesothelioma, as discussed below (Bocchetta et al.,
2000). The purpose of this review is to explore what is
known about the molecular biology of the SV40, BK, and
JC polyomaviruses and how this may be relevant to their
relative involvement in human cancer.
Life cycle of polyomaviruses
The infection of cells by polyomaviruses is initiated by
the binding of the virion to a receptor on the outside of the
cell membrane. In the case of SV40, this receptor has been
identified as the major histocompatibility complex (MHC)
(Norkin, 1999). Because nearly every cell type expresses
MHC molecules, it would be expected that SV40 should be
able to infect most cells. In the case of BKV and JCV, the
cell receptors are not fully understood. It has been reported
that JCV binds specifically to certain cell types (glial cells,
tonsillar stromal cells, and B but not T lymphocytes) that
reflect JCV’s cell tropism (Wei et al., 2000). However, more
recent reports indicate that JCV can enter a broad spectrum
of mammalian cell types through binding to oligosacchar-
ides ubiquitously present on glycoproteins and glycolipidson the cell membrane. After the viral DNA enters the
nucleus, cell-specific intranuclear mechanisms suppressed
JCV DNA replication in all cells except human neuroblas-
toma cell lines in these experiments (Komagome et al.,
2002; Suzuki et al., 2001). In the human body, it is thought
that JCV can infect cells in the tonsils and spread from there
by replication in lymphoid cells (Monaco et al., 1998). BKV
can also replicate in human lymphocytes (Portolani et al.,
1985). JCVand BKV can infect cells in the kidney, which is
the major organ of JCV and BKV persistence during latency
(Chesters et al., 1983). In monkeys, initial lytic infection by
SV40 is controlled by the immune system with virus then
persisting in the kidney where it may be reactivated by
immunosuppression (Horvath et al., 1992). The life cycle of
SV40 in humans is poorly understood (Garcea and Imperi-
ale, 2003).
After binding to the cell surface, polyomavirus capsids
undergo endocytosis and are transported to the nucleus
where the viral DNA is uncoated and transcription of the
early region begins. Interestingly, SV40 enters cells by
caveola-mediated endocytosis (Anderson et al., 1996) al-
though JCVemploys a clathrin-dependent mechanism that is
blocked by tyrosine-specific protein kinase inhibition (Quer-
bes et al., 2004).
The primary transcript from the early region is alterna-
tively spiced to give two mRNAs that encode T-Ag and t-
Ag. T-Ag is a large nuclear phosphoprotein and is an
essential factor for viral DNA replication. It binds to the
viral origin of replication region (ori) where it promotes
unwinding of the double helix and recruitment of cellular
proteins that are required for DNA synthesis including DNA
polymerase-a and replication protein A (Dean et al., 1987;
Dornreiter et al., 1990; Melendy and Stillman, 1993; Stahl
et al., 1986).
Polyomaviruses rely on cellular enzymes and cofactors
for DNA replication and these proteins are expressed in S
phase. Another major function of T-Ag is to modulate
cellular signaling pathways to induce cells to enter S
phase and this accounts for the ability of T-Ag to
transform cells. T-Ag is thought to stimulate the cell cycle
through its ability to bind to several cellular proteins that
are involved and in crucial signal transduction pathways
that control cell cycle progression and apoptosis. These
functions of T-Ag are discussed below. What is known
about T-Ag function for each polyomavirus is summarized
in Table 1.
The role of the small t-Ag in the polyomavirus life cycle
is less clear. Analysis of SV40 deletion mutants revealed
that t-Ag is not essential for lytic infection in culture (Shenk
et al., 1976). However, t-Ag cooperates with T-Ag in the
transformation of cells by SV40 (Martin et al., 1979; Sleigh
et al., 1978) and increases virus yield in permissive cell
infections (Rundell and Parakati, 2001). The mechanism of
action of t-Ag is discussed below.
As viral replication proceeds, the late genes begin to be
expressed. T-Ag acts to stimulate transcription from the
Table 1
Molecular mechanisms of polyomavirus transformation
Mechanism Virus Status References
Large T-Ag
Binding SV40 M DeCaprio et al., 1988
to pRb JCV M Krynska et al., 1997
BKV M Harris et al., 1996
Binding SV40 M Pipas and Levine, 2001
to p53 JCV M Bollag et al., 1989
BKV M Bollag et al., 1989
J domain SV40 M Sullivan and Pipas, 2002
JCV M Sullivan et al., 2000
BKV ?
Binding
to IRS-1
SV40 M Fei et al., 1995;
Prisco et al., 2002
JCV M Khalili et al., 2003a,
2003b; Lassak et al., 2002
BKV ?
Binding to SV40 ?
h-catenin JCV M Enam et al., 2002;
Gan et al., 2001
BKV ?
Induction
of genetic
SV40 M Theile and Grabowski, 1990;
Ray et al., 1990, 1992
instability JCV M Neel et al., 1996;
Ricciardiello et al., 2003;
Theile and Grabowski, 1990
BKV M Theile and Grabowski, 1990;
Trabanelli et al., 1998
Agnoprotein
SV40 ?
JCV M Del Valle et al., 2002
BKV ?
Small t-Ag
Inactivation SV40 M Sontag et al., 1993
of PP2A JCV ?
BKV ?
The three polyomavirus proteins that have been shown to be involved in
transformation are listed on the left together with their known mechanisms
of action. For each virus, a ‘‘M’’ in the status column indicates that this
mechanism has been demonstrated to occur. A ‘‘?‘‘ in the status column
indicates that it is presently unknown whether the mechanism is utilized by
the particular virus.
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promoter. The gene products of the late region are the
capsid proteins VP1, VP2, and VP3, which assemble with
the replicated viral DNA to form virions, which are
released upon cell lysis.
Polyomavirus DNA can become integrated into the
chromosomal DNA of the cell especially upon nonpermis-
sive infection. This was first described for SV40 (Hirai et
al., 1971) and is also the case for JCV (Mandl and Frisque,
1986) and BKV (Chenciner et al., 1980). Integration
occurs at random both in terms of the site in the cellular
genome where integration occurs and the point in the viral
genome where recombination occurs (Hara and Kaji,
1987).
Infections in humans by polyomaviruses are usually
restricted by the actions of the immune system, particularlycell-mediated immunity. For JCV, a general impairment of
the Th1-type T-helper cell function of cell-mediated immu-
nity has been found in the disease progressive multifocal
leukoencephalopathy (PML) (Weber et al., 2001). PML is
discussed below. Cell-mediated immunity is also important
in BKV infection (Drummond et al., 1985).
Mechanisms of oncogenic transformation by
polyomaviruses
Polyomavirus genomes do not encode replication pro-
teins and so they must drive cells into S phase where host
DNA replication proteins are produced. A major mechanism
by which this is achieved is through the action of the early
proteins large T-Ag and small t-Ag (discussed below). T-Ag
interferes with two tumor suppressor proteins that regulate
cell cycle progression, pRb and p53. This aberrant stimula-
tion of the cell cycle is a driving force for oncogenic
transformation.
pRb sequesters the E2F family of transcription factors
that promote the G1/S phase transition thereby preventing
expression of E2F-dependent genes such as c-fos and c-
myc whose products are needed for entry into S phase.
During the cell cycle, CDK4 and CDK6 cause phosphor-
ylation of pRb in late G1 allowing release of the E2F
transcription factors allowing S phase progression (Wein-
berg, 1995, 1996). The T-Ags of all three polyomaviruses
bind to pRb and displace E2F thereby promoting cell cycle
progression. This is a major mechanism whereby T-Ag
promotes the inappropriate cell proliferation characteristic
of oncogenically transformed cells (Cress and Nevins,
1996; DeCaprio et al., 1988; Harris et al., 1996; Krynska
et al., 1997). The Rb-binding domain of T-Ag is highly
conserved between JCV and BKV but not between JCV/
BKV and SV40 (Table 2) perhaps explaining the lower
affinity for pRb exhibited by JCV and BKV T-Ags
compared to SV40 T-Ag (Harris et al., 1998; Tavis et
al., 1994).
p53 protein is a tumor suppressor encoded by a gene
whose disruption is associated with f50–55% of all
human cancers. p53 protein acts as a checkpoint in the cell
cycle and regulates apoptosis. The release of E2F from pRb
by T-Ag activates p14ARF expression that leads to the
stabilization of p53. However, polyomavirus T-Ags bind
to and inactivate p53 and thus prevent inhibition of the cell
cycle or apoptosis (Fig. 1). This is important for providing
an optimal cell environment for viral replication and pack-
aging during polyomavirus lytic infection and facilitates
transformation in nonpermissive cells (Levine, 1997; Vogel-
stein et al., 2000). Interaction of T-Ag with p53 has been
demonstrated for SV40 (Pipas and Levine, 2001) and for
JCV and BKV (Bollag et al., 1989). It has been reported
that the subpopulation of T antigen that forms a stable
complex with cellular p53 protein was smaller in JCV-
transformed cells than in SV40- or BKV-transformed cells
(Bollag et al., 1989).
Table 2
Conservation of amino acid sequences between polyomavirus oncoproteins
Position JC/BK
(%)
JC/SV40
(%)
BK/SV40
(%)
Large T
Overall (1–708) 83 73 74
J domain (1–100) 88 82 80
Rb domain (101–118) 88 71 67
DNA binding (131–259) 87 82 83
p53/ATP-ase (350–610) 85 79 79
C terminus (620–708) 65 47 47
Small t
Overall (1–172) 78 67 70
J domain (1–83) 89 82 82
PP2A domain (84–172) 69 56 63
Agnoprotein
Overall (1–62) 80 59 63
The table shows the percentage of amino acid (aa) sequence identity between
the oncogenes of the primate polyomaviruses and selected subregions.
Sequences were extracted from GenBank for the Mad-1 strain of JCV
(J02226), the Dunlop strain of BKV (V01108) and the 776 strain of SV40
(AF316139). Large T antigens are 688, 695, and 708 aas long for JCV, BKV,
and SV40, respectively: for small t, 172, 172, and 174 aas: for Agnoproteins,
66, 71, and 62 aas. The numbers in brackets show the position relative to the
N terminus of the SV40 protein. The position of the domains within SV40 T/
t antigens was taken from information presented in two recent reviews
(Frisque and White, 1992; Saenz-Robles et al., 2001).
Overall T-Ag is highly conserved with functional domains showing even
higher degrees of homology with two exceptions. The C terminus of T-Ag
(which determines host range) is much less conserved. The Rb-binding
domain of T-Ag is highly conserved between JCV and BKV (88%) but not
between JCV/BKV and SV40 (71/67%). This may provide an explanation
for the observation that JCV and BKV T-Ags do not bind pRb as well as
SV40 T-Ag (Tavis et al., 1994; Harris et al., 1998).
Small t can be divided into two regions based on the position of occurrence
of alternative splicing (between aa 83 and aa 84). The N terminus is
identical to aas 1–83 in the J domain of T-Ag and similarly shows a high
degree of conservation. The C terminus which, in SV40, binds PP2A
(Table 1) is much less conserved in JCV and BKV (56% and 63%).
Interestingly, the Agnoproteins are conserved between JCV and BKV
(80%) but not between these two viruses and SV40 (59% and 63%),
suggesting that there may exist differences in function (see Table 1).
Fig. 1. Functions of large T antigen. Large T antigen (T-Ag) binds to the
retinoblastoma virus susceptibility protein pRb causing the release of the
transcription factor E2F that is responsible for inducing the expression of
many genes involved in the advancement of the cell cycle. However, E2F
also induces p14ARF gene expression. p14ARF protein interferes with the
activity of MDM2 that is in turn a negative regulator of p53.
Consequently, p53 is stabilized, which would inhibit the cell cycle and
promote apoptosis. T-Ag counteracts this by binding and inactivating p53
(Vogelstein et al., 2000). Interaction of T-Ag with other cellular proteins is
important in transformation. T-Ag binds to IRS-1 causing it to be
translocated to the nucleus (Lassak et al., 2002). This may be important in
Rad51 trafficking and homologous recombination-directed DNA repair
(Trojanek et al., 2003). T-Ag also binds to h-catenin and enhances
expression of c-myc and cyclin D1 (Coyle-Rink et al., 2002; Enam et al.,
2002; Gan et al., 2001).
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other signaling proteins besides pRb and p53. JCV T-Ag has
been shown to directly bind to insulin receptor substrate 1
(IRS-1) and cause it to be translocated to the nucleus. A
dominant negative mutant of IRS-1 inhibited growth and
survival of JCV T-Ag-transformed cells in anchorage-inde-
pendent culture conditions demonstrating the importance of
this interaction in cell transformation (Lassak et al., 2002).
There is growing evidence that the interaction of JCV T-Ag
with IRS-1 contributes to the process of malignant transfor-
mation in childhood medulloblastomas and this has been
reviewed recently (Khalili et al., 2003a, 2003b). The con-
sequences of IRS-1 nuclear translocation are still being
characterized but one possibility is that it may be important
in Rad51 trafficking and homologous recombination-direct-
ed DNA repair (Trojanek et al., 2003). There is also
evidence that interaction with IRS-1 is involved in transfor-mation by SV40 T-Ag (Fei et al., 1995; Prisco et al., 2002),
but a role for IRS-1 in BKV T-Ag transformation has not
been explored (Table 1).
JCV T-Ag has also been shown to directly bind to h-
catenin (Enam et al., 2002; Gan et al., 2001). The interaction
of T-Ag with h-catenin occurs through the central domain of
T-Ag spanning residues 82–628, and the C terminus of h-
catenin located between amino acids 695 and 781. The
association of T-Ag with h-catenin increases the level of h-
catenin in the cell due to increased protein stability (Gan et
al., 2001). This interaction causes h-catenin to translocate to
the nucleus where it enhances expression of genes such as c-
myc and cyclin D1. These observations ascribe a new
mechanism for the deregulation of the Wnt pathway through
stabilization of h-catenin. The Wnt pathway signals to the
downstream transcription factors TCF-4 and LEF-1 (Wong
and Pignatelli, 2002). These signaling events may be
important in certain human cancers that are associated with
JCV such as medulloblastoma and colon cancer (Coyle-
Rink et al., 2002; Enam et al., 2002; Gan et al., 2001).
Recently, it has been shown that Epstein–Barr virus also
activates Wnt pathway signaling in epithelial cells (Morri-
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2003).
An important conserved motif known as the J domain is
found at the N terminus of T-Ag. This was discovered from
sequence similarity between the N terminus of T-Ag and the
J class of chaperonins (Sullivan and Pipas, 2002). Domain-
swapping experiments have shown that the N terminus of T-
Ag can functionally substitute for the J domain of E. coli
DnaJ (Kelley and Georgopoulos, 1997). J proteins are
cochaperonins for the DnaK (Hsp70) family of proteins
(Sullivan and Pipas, 2002). The N terminus of T-Ag
functions as a J protein in assays in vitro, for example,
stimulation of bovine Hsp70 ATP-ase activity (Srinivasan et
al., 1997). The J domain is essential for many of the
functions of T-Ag including DNA replication. In addition
to the Rb-binding domain (amino acid residues 101–118),
the J domain of T-Ag is required in cis for binding to the Rb
family of proteins. The role of the J domain in other aspects
of transformation is complex and has been reviewed recent-
ly (Sullivan and Pipas, 2002). Although much remains to be
elucidated about the exact biophysical nature of the inter-
actions of T-Ag and cellular proteins, it seems likely that the
chaperonin functionality of T-Ag will turn out be an
important determinant in the ability of T-Ag to bind to
many of its cellular targets. Thus, T-Ag is a highly multi-
functional protein that can bind a plethora of cellular
proteins and affect many cellular pathways of growth
control.
As well as being able to transform cells by virtue of
interacting with cellular signaling proteins, the T-Ag of
primate polyomaviruses has a mutagenic effect on cellular
DNA. It seems likely that secondary mutations induced by
T-Ag contribute to the tumorigenicity of infected cells.
Theile and Grabowski (1990) reported increases in sponta-
neous mutation frequencies up to 100-fold when cultured
cells were infected with BKV. The variant strain BKV-IR,
which does not express small t-Ag, was also mutagenic.
Besides cultured cells, BKV was also able to induce gene
mutations in human peripheral blood lymphocytes. These
studies also compared the mutagenicities of DNAs from
BKV, JCV, and the mutagenic effects of the three viruses
were essentially the same.
Primate polyomavirus T antigen also induces karyotypic
changes. Human fibroblasts transfected with plasmid con-
taining the BKV early region exhibited cytogenetic damage
including deletions and translocations. This damage preced-
ed morphological transformation (Trabanelli et al., 1998).
Ricciardiello et al. (2003) showed that JCV caused chro-
mosomal instability in human colonic cells. (A role for JCV
in colon cancer is discussed below.) Ray et al. (1990, 1992)
constructed a plasmid containing SV40 large T-Ag driven
by the Rous sarcoma virus promoter but lacking small t-Ag
and the SV40 origin. When this was transfected into human
fibroblasts, 99% of T-Ag-positive clones exhibited numer-
ical or structural chromosome aberrations. These changes
were evident before the transformation indicators of theclones were positive and continued throughout neoplastic
progression. Antibody titers to BKV and JCV have been
correlated with the occurrence of ‘‘rogue cells’’—lympho-
cytes with multiple chromosome aberrations (Lazutka et al.,
1996; Neel et al., 1996). Recently, it has been reported that
SV40 T-Ag interferes with DNA repair (Digweed et al.,
2002).
In the case of SV40 T-Ag, recent research has revealed a
possible molecular mechanism for the induction of chromo-
somal instability. It is known that karyotypic changes are
induced by large T-Ag but not small t-Ag in human diploid
fibroblasts and embryonic kidney cells (Stewart and Bac-
chetti, 1991), and this function maps to the N-terminal 147
amino acid residues of T-Ag (Woods et al., 1994). Using the
yeast two-hybrid system with the N terminus of SV40 T-Ag
as bait, it has recently been shown that T-Ag binds to the
mitotic checkpoint protein Bub-1 (Cotsiki et al., 2004). T-
Ag is known to disrupt the mitotic checkpoint and attenuate
radiation-induced mitotic delay (Chang et al., 1997), sug-
gesting that this is a mechanism of T-Ag induction of
chromosome aberrations and aneuploidy.
Taken together, these data indicate that genetic instability
induced by T-Ag is likely an important contributor to
polyomavirus-induced oncogenesis. Because p53 is inacti-
vated by T-Ag, the elimination of mutated cells by p53-
mediated apoptosis would be expected to be impaired. This
is likely to be of central importance in the etiology of cancer
after polyomavirus infection. Although the inactivation of
pRb, p53, and other cellular proteins by T-Ag is enough to
dysregulate the cell cycle and produce a ‘‘transformed
phenotype’’ in cultured cells, apparently, acquisition of
other mutations is necessary for cells to be able to grow
progressively in vivo (tumorigenicity). In this regard, trans-
formation can clearly be separated from tumorigenicity in
somatic cell genetic experiments (Gee and Harris, 1979).
There are many phenotypic cellular and biochemical
changes that are associated with transformation by T-Ag,
and these include growth to high saturation density, focus
formation, growth in soft agar, serum-independence, mor-
phological changes, elevated glucose uptake, plasminogen
activator production, and so forth (Saenz-Robles et al.,
2001). The known molecular mechanisms of transformation
for each polyomavirus are summarized in Table 1.
The second of the two proteins encoded by the early
region of primate polyomaviruses is small t antigen (t-Ag).
The N-terminal 82 amino acids are the same as the N
terminus of large T-Ag but the C terminus is a unique
domain that is incorporated by alternative splicing of the
early region primary transcript. Published research on
primate polyomavirus small t-Ag has concentrated almost
exclusively on SV40. SV40 t-Ag has a mitogenic role in
the transformation of cells (Martin et al., 1979; Sleigh et
al., 1978). Protein phosphatase 2A (PP2A) is bound and
inhibited by SV40 small t-Ag (Pallas et al., 1990). Phos-
phatases are negative regulators of growth promoting
signal transduction pathways. PP2A is the major serine-
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cells (Cohen, 1997). By inactivating the negative regulator
PP2A, t-Ag is able to activate several pathways that
promote cell proliferation including the centrally important
mitogen-activated protein kinase (MAPK) pathway (Sontag
et al., 1993). It is not clear if this is true for JCV and BKV
(Table 1), and indeed the C terminus of t-Ag (where PP2A
binds) for these viruses is only moderately homologous to
that of SV40 (Table 2). However, the t-Ag of all three
viruses contains two conserved cysteine cluster motifs
(CXCXXC) (Pipas, 1992) that are thought to be involved
in the interaction of t-Ag with PP2A (Mateer et al., 1998).
Indeed, two cellular proteins were specifically co-immu-
noprecipitated with BK virus t-Ag that may be subunits of
PP2A (Rundell et al., 1981).
In addition to T-Ag and t-Ag, there is emerging evidence
for a role in cell transformation for a third viral protein. A
small protein known as Agnoprotein is encoded near the 5V
end of the late region. Agnoprotein is 62, 71, and 66 amino
acid residues long for SV40, JCV, and BKV, respectively
(Cole, 1996), and is produced late in the infectious cycle
although it is not incorporated into virions (Cole, 1996; Jay et
al., 1981). The predominant intracellular localization of
Agnoprotein is in the cytoplasm and especially the perinu-
clear region in association with the outer nuclear membrane
for all three primate polyomaviruses (Nomura et al., 1983;
Okada et al., 2001; Rinaldo et al., 1998). A small amount
Agnoprotein is also found in the nucleus for JCV and SV40
(Nomura et al., 1983; Okada et al., 2001), but not for BKV
(Rinaldo et al., 1998). Interestingly, BKV Agnoprotein is
phosphorylated and associates with three cellular proteins
(Rinaldo et al., 1998). Agnoprotein has a role in the lytic
cycle because SV40 mutants in which the Agnogene is
deleted produce virions more slowly than wild-type virus
(Ng et al., 1985). Agnoprotein may have regulatory roles in
viral transcription, translation, as well as in virion assembly
and maturation. It has been reported that Agnoprotein serves
to localize VP1 to the perinuclear space during lytic infection
(Carswell and Alwine, 1985; Resnick and Shenk, 1986).
Functions of Agnoprotein have been reviewed recently
(Safak and Khalili, 2003). The Agnoprotein of JCV can
interact with the cellular YB-1 transcription factor to regulate
JCV transcription (Safak and Khalili, 2001; Safak et al.,
2002) and also can cause dysregulation of the cell cycle
(Darbinyan et al., 2002). At least in the case of JCV,
Agnoprotein binds directly to p53 (Darbinyan et al., 2002).
JCV Agnoprotein dysregulates cell cycle progression when
expressed in the absence of other viral proteins (Darbinyan et
al., 2002). Constitutive expression of JCV Agnoprotein
causes cells to accumulate at the G2/M stage of the cell cycle
with a decline in cyclins A and B-associated kinase activity.
Agnoprotein augments the activity of the p21/WAF-1 pro-
moter and the level of p21/WAF-1. Activation of p21/WAF-1
gene expression is mediated, at least in part, through coop-
eration with p53 (Darbinyan et al., 2002). JCVAgnoprotein
may also be important in malignancy (discussed below).Involvement of polyomaviruses in human cancers
In this section, evidence of a role in neoplasia will be
examined for the three primate polyomaviruses: JCV, BKV,
and SV40. Where possible, molecular correlates will be
elaborated for the observed differences in the patterns of
tumor formation between theses three viruses. Essentially,
data can be divided into three categories: transformation of
cells in culture, oncogenic potential in laboratory animals,
and association with clinical human tumors.
JCV
JCV is widespread throughout the human population
with f80% of adults exhibiting antibodies specific for
JCV. Infection is thought to occur during early childhood
and is usually subclinical. However, under immunosuppres-
sive conditions, for example, in patients with acquired
immunodeficiency syndrome (AIDS), JCV can emerge from
latency and cause progressive multifocal leukoencephalop-
athy (PML) (Gordon and Khalili, 1998; Safak and Khalili,
2003). PML is a neurodegenerative disease of the central
nervous system characterized by multiple regions of demy-
elination. Lytic infection of oligodendrocytes by JCV
destroys myelin-producing cells leading to brain lesions
and death (Berger, 2003). PML used to be considered a
rare disease, but since the advent of the AIDS pandemic, it
is much more prevalent and affects f5% of HIV-infected
persons (Berger, 2003).
JCV is able to transform cells in culture although not as
efficiently as SV40. JCV can transform human fetal glial
cells and primary hamster brain cells. JCV-transformed cells
exhibit the phenotypic properties associated with transfor-
mation including growth in soft agar, serum-independence,
morphology, plasminogen activator production, and so
forth. These studies have been reviewed recently (Del Valle
et al., 2001a).
The transforming ability of JCV appears to be limited to
cells of neural origin and this property maps to the viral
regulatory region at the origin of replication. Specifically,
the JCV early promoter (JCVE) directs glial cell-specific
transcription of the large T antigen (T-Ag). Glial cell-
specific transcriptional regulation of JCV-T-Ag expression
by JCVE is believed to be a major determinant of the neural
tropism of JCV in PML (Henson et al., 1995; Kim et al.,
2001).
The following lines of evidence indicate that JCVE is
glial-specific. JCVEDreporter gene constructs are expressed
at higher levels in glial cells than in nonglial cells (Kenny
et al., 1984). Transgenic mice with the JCV early region
selectively express T-Ag in oligodendrocytes leading to a
phenotype of dysmyelination (Trapp et al., 1988). Trans-
genic mice with constructs in which the early promoters
and T-Ag regions of JCV and SV40 were exchanged
showed patterns of expression that demonstrated that the
JCVE promoter was responsible for glial-specific expres-
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Table 3
Tumors induced in transgenic mice by human polyomavirus gene
expression
T antigen Phenotype Reference
JCV adrenal
neuroblastoma
Small et al., 1986a
neuroectodermal
tumors
Franks et al., 1996
primitive tumors
originating from
the cerebellum
Krynska et al., 1999b
pituitary neoplasia Gordon et al., 2000
BKV hepatocellular
carcinomas/renal tumors
Small et al., 1986a
renal tumors and
thymomas or lymphoma
Dalrymple and
Beemon, 1990
SV40 choroid plexus tumors Brinster et al., 1984;
Messing et al., 1985
The table lists the types of tumors induced in transgenic mice containing T
antigen from each of the primate polyomaviruses. In each case, T-antigen
expression is driven by its own promoter. Experiments in which T-Ag
expression is driven by heterologous promoters have been reviewed
recently (Saenz-Robles et al., 2001).
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showed that hamster glial cell extract stimulated JCVE
whereas HeLa cell extract reduced production of nuclear
run-off transcripts. This suggests that glial cells contain an
activating factor(s) for JCVE transcription although nonglial
(HeLa) cells contain a repressor(s) (Ahmed et al., 1990a,
1990b).
Detailed analyses of the JCVE promoter have shown that
transcription is regulated in a complex fashion. Multiple
transcription factors, both general and cell-specific, regulate
JCVE including Jun, NF-1, GF-1, Sp1, SAbp-2, Pura, and
YB-1 (reviewed recently (Kim et al., 2001; Raj and Khalili,
1995)).
Thus, in JCV, we have compelling molecular evidence
for the basis for the tissue-specificity of viral tropism in cell
culture and in vivo (discussed below).
Many studies have established the highly oncogenic
potential of JCV in laboratory animals, for example, JCV
induced multiple types of brain tumors when injected into
the brains of newborn Golden Syrian hamsters. JCV is the
only polyomavirus that induces solid tumors in nonhuman
primates. JCV caused the development of astrocytomas,
glioblastomas, and neuroblastomas in owl and squirrel
monkeys that occurred 16–24 months after inoculation of
JCV intracerebrally, subcutaneously, or intravenously (Lon-
don et al., 1978, 1983). Study of monkey tissue revealed T-
Ag expression but no capsid protein or infectious virion
indicating monkey cells is nonpermissive for JCV replica-
tion (Major et al., 1992). JC viral DNA is integrated into
cellular DNA in JCV-induced tumors of owl monkeys
(Miller et al., 1984). These animal studies have been
reviewed recently (Del Valle et al., 2001a; Khalili et al.,
2003a, 2003b). As mentioned above, transgenic mice
expressing JCV T-Ag can develop dysmyelinating disease.
These mice can also develop adrenal neuroblastomas (Small
et al., 1986a, 1986b). Franks et al. (1996) generated a line of
transgenic mice with the JCV T-Ag gene and these mice
exhibit tumors of primitive neuroectodermal origin. Trans-
genic mice with the JCV T-Ag can develop tumors that arise
from the pituitary gland (Gordon et al., 2000). Data from
transgenic mice are summarized in Table 3.
Does JCV have a role in human cancer? An indication
that this is the case came from reports of brain tumors being
found in patients with PML (reviewed in (Gallia et al.,
1998)). JCV has also been associated with brain tumors in
patients without PML. For example, Rencic et al. (1996)
were able to detect JCV DNA by PCR in tumor tissue from
a patient with oligoastrocytoma. The identity of the ampli-
fied PCR product with JCV was confirmed by DNA
sequencing. Moreover, JCV RNA and T-Ag protein were
detectable by primer extension analysis and Western blot-
ting, respectively, indicating gene expression. Del Valle et
al. (2001b) examined 85 samples of tumors of glial origin
for JCV DNA and T-Ag expression. It was found that 57–
83% of tumors were positive depending on tumor type.
Krynska et al. (1999a) detected JCV T-Ag DNA sequencesin 11 of 23 pediatric medulloblastomas, and 5 of these 11
were also positive for SV40 DNA sequences. SV40 and
cancer is discussed below. In another study on JCV, Agno-
gene DNA was detected in 11 of 16 medulloblastoma
samples and Agnoprotein expression in 11 of 20 samples.
Because some of the Agnoprotein positive medulloblastoma
samples were negative for concomitant T-Ag expression,
Agnoprotein may have a role in the development of JCV-
associated medulloblastoma (Del Valle et al., 2002). Many
other studies that have employed PCR-mediated DNA
amplification or immunohistochemistry of various brain
samples provide support for an association of JCV with a
wide variety of tumors of the central nervous system (CNS)
and in other tumors such as colon cancer.
JCV DNA sequences have been found in a high percent-
age of normal tissue samples taken from the upper and
lower human gastrointestinal tract (Ricciardiello et al.,
2000) and in sewage (Bofill-Mas and Girones, 2001). In a
study of epithelial malignant tumors of the large intestine,
22 of 27 samples tested positive for JCV DNA sequences.
Expression of JCV T-Ag and Agnoprotein was observed in
>50% of the samples (Enam et al., 2002). No expression of
JCV proteins was detected in normal gastrointestinal epi-
thelial tissue. Thus, JCV is associated with some colon
cancers and evidence has been presented that dysregulation
of h-catenin signaling by JCV T-Ag is involved (Enam et
al., 2002; Gan et al., 2001). The involvement of JCV in
brain and nonbrain tumors has recently been reviewed (Del
Valle et al., 2001a).
Studies of JCV have provided us with a consistent story
for the pattern of oncogenesis of this virus. Molecular studies
show a glial cell-specific requirement for transcription from
the JCVE promoter and hence JCV T-Ag expression. Trans-
genic mice with a JCVE promoter driving JCV-T-Ag transgene
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(Table 3). In humans, JCV is associated with the brain
disease PML and with tumors of the CNS. For JCV and
brain tumors, there is an impressive array of evidence that
fits biologically and does not rely only on PCR.
BKV
Like JCV, BKV is widespread in the human population
with more than 63% of individuals testing serologically
positive. Primary infection occurs during childhood and is
usually subclinical. However, BKV can reactivate from
latency under conditions of immunocompromization, in-
cluding pregnancy, transplantation, and AIDS, to cause
nephropathy. Notably, kidney transplant recipients who
receive highly immunosuppressive drugs may develop
BKV-associated nephropathy that is a leading cause of
allograft failure (Hirsch and Steiger, 2003; Moens and
Rekvig, 2001; Nickeleit et al., 2002).
BKV, BKV complete genomic DNA, or BKV genomic
fragments that include the early region are able to transform
embryonic fibroblasts and cells cultured from the kidney or
brain of mouse, rat, hamster, rabbit, and monkey (Corallini
et al., 2001; Tognon et al., 2003). The efficiency of
transformation is variable and dependent upon genetic
features of the viral strain that is used. The efficiency of
BKV T-Ag-induced transformation of hamster cells was
improved by the co-introduction of the human c-Harvey-
ras oncogene (Pagnani et al., 1988). In the case of human
cells, transformation of human embryonic kidney (HEK)
cells by BKV is not efficient and often abortive. Features of
the transformed phenotype are not fully displayed. Howev-
er, a fully transformed phenotype can be achieved in
cooperation with other oncogenes such as adenovirus
E1A, c-rasA, or c-myc (Corallini et al., 2001).
BK virus is highly oncogenic in young or newborn mice,
rats, and hamsters. The efficiency of tumorigenesis by BKV
in hamsters is dependent upon the route of injection. BKV is
only weakly oncogenic when injected subcutaneously but
gives a high incidence of tumors when injected intracere-
brally or intravenously. The types of tumors induced include
ependymoma, neuroblastoma, pineal gland tumors, pancre-
atic islet tumors, fibrosarcoma, and osteosarcoma. This
suggests that BKV has a tropism for certain cell types
(Corallini et al., 2001).
In studies that were conducted in parallel with the
experiments analyzing the JCV early region (see JCV
section), Small et al. (1986a) also established transgenic
mice containing the BKVearly region. As was the case with
JCV, a highly tissue-specific production of tumors was
observed but the tissue distribution of BKV-induced tumors
differed from that of JCV (Table 3). BKV-containing mice
developed primary hepatocellular carcinomas and renal
tumors. Dalrymple and Beemon (1990) also established
mice containing the BKV early region. They observed two
types of pathology: enlarged thymuses (ranging from hy-perplasia to thymomas and lymphomas) and renal adeno-
carcinoma. Expression of BKV T-Ag in these mice was
restricted to epithelial cells of kidney tumors and the
enlarged thymuses. No expression was detected in any
normal tissues.
Does BKV have a role in human cancer? BKV DNAwas
detected by Southern blot hybridization in 19 out of 74 brain
tumors and in 4 out 9 pancreatic islet tumors. In some of
these tumors, BKV RNA and T-Ag expression could be
detected (Corallini et al., 1987). Interestingly, BKV was
found to be in an episomal state at a copy number of 0.2–2
genomes/cell. (Occasionally, tumors had 10–20 genome
copies per cell.) Dorries et al. (1987) reported BK DNA
by Southern blot hybridization in 46% of 11 common
histotypes. In this report, BKV DNA sequences were found
to be integrated into chromosomal DNA. Flaegstad et al.
(1999) reported BKV DNA detected by PCR in 17 of 18
neuroblastomas and T-Ag expression by immunohistochem-
istry in 16 of 18. For two samples in this study, T-Ag was
also detected by Western blotting after co-immunoprecipi-
tation with p53. However, Arthur et al. (1994) reported a
lack of association of BKV DNA with brain tumors (pri-
marily, glioblastoma multiforme) using PCR. Whether these
are real differences or due to differences in PCR sensitivity
is unclear. This issue is discussed in the next section. More
studies are warranted to look at the association of BKV with
brain tumors.
BKV was detected in a patient with an adenoma of the
pancreatic islets (insulinoma), and a variant of BKV (BKV-
IR) was isolated by transfecting human fibroblasts with
DNA isolated from the tumor (Caputo et al., 1983). The
association of BKV with pancreatic islet tumors is consis-
tent with its pattern of tumorigenesis in laboratory rodents
(discussed above). There have been many other reports of
the detection of BKV DNA in human tumors by PCR and
Southern blotting. These include Kaposi’s sarcoma, brain
tumors, and tumors of the urinary tract. These reports have
been reviewed recently (Corallini et al., 2001).
Therefore, BKV shows important differences from JCV
including reduced ability to transform cells in culture, a
distinct pattern of tumor formation in laboratory animals,
and a different clinical profile in humans. It is possible that
these properties of BKV are related to the cell-type specific-
ities of the early promoter as was described above for JCV.
However, less is known about the molecular mechanisms of
oncogenesis for BKV than for JCV. The relative roles of the
intrinsic oncoprotein activity of T-Ag versus the specific
characteristics of the BKV early promoter in determining
BKV pathology have not been determined. In this regard, it
would be interesting to investigate hybrid constructs where
the BKV early promoter and the BKV T-Ag coding region
have been swapped with the corresponding regions of other
polyomaviruses as has been done for JCV (Feigenbaum et
al., 1992).
The role of BKV in human malignancy is uncertain.
From the standpoint of establishing a firmer verification of
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recent technologies, for example, the application of laser
capture microdissection of tumor samples to verify the
presence and specificity of BKV DNA and expression of
viral proteins.
SV40
Unlike JCV and BKV, it is widely accepted that the
natural host for SV40 is the rhesus monkey and not the
human. However, nearly 100 million people in the United
States alone are estimated to have been exposed to SV40
inadvertently through poliovirus vaccinations between 1955
and 1963. This was because primary cultures of rhesus
monkey kidney cells that were used to grow the poliovirus
were contaminated with SV40. SV40 is a potent trans-
forming agent for cell cultures from species that are non-
permissive for viral replication including hamsters, mice
rats, cattle, and guinea pigs (Arrington and Butel, 2001).
Most of the early studies on SV40 transformation were done
with established rodent cell lines such as Balb-3T3 cells. As
was described above, SV40 can enter these cells and express
the early region (T-Ag) but does not replicate or express the
late genes. Cells undergo many cellular and biochemical
changes after SV40 transformation as described above
(Saenz-Robles et al., 2001).
SV40 is also able to induce tumor formation in labora-
tory animals. Soon after its discovery, the oncogenic poten-
tial of SV40 was demonstrated in that it induced sarcoma
formation after subcutaneous injection into hamsters (Eddy
et al., 1962). Like BKV (see above), tumorigenesis by SV40
is dependent upon the route of injection. Hamsters injected
intravenously with SV40 develop leukemia, lymphoma, and
osteosarcoma (Diamandopoulos, 1972), whereas hamsters
injected intracranially develop choroid plexus tumors and
ependymomas (Kirschstein and Gerber, 1962), and hamsters
injected intrapleurally develop mesothelioma (Cicala et al.,
1993).
Transgenic mice bearing the SV40 T-Ag develop char-
acteristic brain tumors localized to the choroid plexus
(Table 3). Deletion analysis showed that localization of
tumors to the choroid plexus region is determined by the
SV40 noncoding regulatory region (Brinster et al., 1984;
Messing et al., 1985). Replacing the SV40 early promoter
with another tissue-specific promoter can direct T-Ag to a
particular tissue and promotes its oncogenesis. For exam-
ple, mice bearing an elastase-1DSV40 T-Ag transgene
develop pancreatic neoplasia (Ornitz et al., 1987). This is
reminiscent of the findings for JCV that viral tropism
depends on the T-Ag promoter. However, many other
experiments of this type have been performed for different
tissues and cell types (reviewed by Saenz-Robles et al.,
2001), and variability has been found depending on the
promoter used and the cell type targeted. Results range
from hyperplasia and carcinoma to no apparent pathology
at all. It is therefore an oversimplification to suggest thatpromoter-specific elements controlling T-Ag expression are
the sole determinants of the ability of T-Ag to transform
particular cell types (Saenz-Robles et al., 2001). Stochastic
effects are probably also a factor in the development of
tumors in transgenic mice as was shown for T-Ag-induced
pancreatic tumors (Christofori et al., 1994; Efrat and
Hanahan, 1989).
Although rodent cells do not support SV40 replication
(and thus infection causes cell transformation) and monkey
cells are permissive for SV40 replication (and thus infection
causes cell lysis), human cells are unique in that they support
transformation and low-level SV40 replication. In other
words, human cells are semipermissive for SV40 replication.
The transformation of human cells by SV40 was first
reported in 1962 (Shein and Enders, 1962). SV40 can
transform many types of human cells in culture. SV40-
transformed human fibroblasts exhibit many of the features
of the transformed phenotypes that were enumerated for
rodent cells (see above). However, unlike rodent cells,
human cells are not immortalized by SV40. Rather, they
exhibit an extended life span: primary human fibroblasts can
undergof50–60 population doublings before they begin to
undergo senescence whereas SV40-transformed fibroblasts
can undergo 70–80 doublings (Arrington and Butel, 2001;
Bryan and Reddel, 1994).
After 70–80 population doublings, SV40-transformed
fibroblasts enter a ‘‘crisis’’ period when most of the cells
die by apoptosis (Macera-Bloch et al., 2002; Ponten, 1971).
The few cells that survive crisis are capable of continuous
cell growth and are termed immortal. The interaction of
SV40 T-Ag with p53 and pRB enables the transformed
phenotype and growth in the extended life span phase.
Immortalization requires additional event(s) caused by the
mutagenic effects of T-Ag (described above) and only
occurs at a frequency of 108–105. One such event is
the inactivation of the tumor suppressor gene SEN6 (Banga
et al., 1997; Jha et al., 1998). Interestingly, ectopic expres-
sion of human telomerase (hTERT) can avert crisis in SV40-
transformed primary cells (Zhu et al., 1999), and indeed
SV40 T-Ag, ras oncogene, and hTERT in combination result
in direct tumorigenic conversion of normal human epithelial
and fibroblast cells (Hahn et al., 1999).
In an early series of interesting studies, Jensen et al.
(1964) demonstrated that SV40 is tumorigenic in humans.
Cells from human volunteer donors were transformed ex
vivo by SV40 and then autologously reimplanted subcuta-
neously. These SV40-transformed cells grew as subcutane-
ous nodules for 2 weeks but then regressed presumably
because of an immune reaction against viral antigens.
Histologically, the nodules were sarcomas. Normal control
cells did not form nodules. This was a one-time study that
would seem unlikely to be approved by contemporary IRBs.
The role of SV40 in the etiology of human cancers is
perhaps one of the most contentious issues in cancer
research today. The first report of an association of SV40
with human cancer was made by Soriano et al. (1974).
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ma metastases from a patient who had antibodies to viral
capsid and T-Ag (Soriano et al., 1974). Since then, there
have been a large number of reports of the association of
SV40 and human tumors and these have been reviewed
recently (Arrington and Butel, 2001). However, no further
studies have been reported on the association of SV40 with
melanoma specifically and it would be interesting to exam-
ine melanomas using modern techniques and find out the
extent of correlation of SV40 with melanoma.
Many reports have described the association of SV40
with mesothelioma, a rare but aggressive cancer of meso-
thelial cells. A major factor in the development of meso-
thelioma is thought to be exposure to asbestos. The frequent
association of SV40 with mesothelioma has led to the
hypothesis that the virus is a cofactor in the development
of this malignancy. In cell culture studies, human mesothe-
lial cells have been found to be nonpermissive for SV40
replication and consequently to undergo cell transformation
in response to SV40 infection. Asbestos was found to be a
synergistic factor for transformation in these experiments
(Bocchetta et al., 2000). It has also been reported that
human mesothelial cells are permissive for BKV replication
but refractory to infection by JCV. This may provide an
explanation as to why SV40 is associated with mesotheli-
oma rather than the more ubiquitous human polyomavi-
ruses, BKV and JCV (Carbone et al., 2003a, 2003b).
Despite the many reports of SV40 in mesothelioma
samples, several studies have failed to detect SV40 sequen-
ces as reviewed recently (Arrington and Butel, 2001). To
address this technical issue, Testa et al. (1998) conducted a
multicenter study. SV40 DNA was detected by PCR using
primers directed at two conserved regions, and positive
clones were verified by Southern blot and sequencing.
Immunostaining of selected samples demonstrated SV40
T-Ag expression. However, another multicenter study
reached the opposite conclusion (Strickler, 2001). The
problematic technical issues that may underlie this contra-
diction have been reviewed recently (Garcea and Imperiale,
2003). The two major concerns are the number of PCR
cycles used in DNA amplification and the specificity of the
antibodies used in immunohistochemistry. A large number
of PCR cycles (40–60) are necessary to detect SV40 DNA,
raising the possibility that there may be fewer than one viral
genome per cell. Furthermore, the antibodies that are used to
detect SV40 T-Ag are cross-reactive with the T-Ags of JCV
and BKV, raising obvious issues of specificity.
SV40 has also been reported to be associated with some
brain tumors (reviewed in Arrington and Butel, 2001) and
with non-Hodgkin lymphoma (Shivapurkar et al., 2002;
Vilchez et al., 2002). The requirement for 45 cycles of
PCR for reproducible detection suggests that the virus was
present in low copy number in non-Hodgkin lymphomas.
Interestingly, SV40 has been found in association with
pediatric tumors of the choroid plexus and ependymomas
using PCR and T-Ag immunohistochemistry (Bergsagel etal., 1992). This is the type of tumor that is seen in transgenic
mice containing the SV40 early region (Table 3). SV40 has
also been detected in some medulloblastomas by PCR and
immunohistochemistry (Huang et al., 1999; Krynska et al.,
1999a, 1999b).
What is the nature of the SV40 DNA that is associated
with human tumors? DNA sequences of SV40 from human
tumors have been isolated and compared to those of
laboratory strains and monkey isolates (Lednicky et al.,
1995; Stewart et al., 1996, 1988). These data yielded the
following conclusions: (1) The SV40 DNA found in human
tumors is authentic. (2) The SV40 DNA sequences found in
human tumors differ from the sequences of the reference
strain SV40-776 and the other laboratory strains (SV40-B2
and VA45-54). This argues against contamination of sam-
ples in the laboratory as a source of the SV40 DNA. The
promoter region of SV40 isolated from monkeys or from
human tumors has a single copy of a 72-bp sequence that is
duplicated in laboratory strains. (This duplication may
represent an adaption to growth in tissue culture.) (3) There
was no compelling evidence for human-specific strains of
SV40 or for tumor type-specific associations.
Recently, more convincing evidence for the association
of SV40 with human cancer has emerged that is free from
the technical caveats of earlier studies that were discussed
above. Mendoza et al. (1998) reported a study of 35
osteosarcoma tumors of which 9 were positive by PCR.
Analysis of total cell DNA from tumors by Southern blot
hybridization found that about half of the PCR-positive
tumors had detectable SV40 DNA that was integrated into
chromosomal DNA (1–4 copies per cell). In another study,
microdissection of mesothelioma frozen tumor revealed the
presence of SV40 DNA sequences in the tumor cells but not
in adjacent nontumorous tissues (Shivapurkar et al., 1999).
Malkin et al. (2001) studied two unrelated patients with Li
Fraumeni syndrome who have one germ-line allele of p53
that is mutated. These patients had multiple tumors and
some were due to loss of the single wild-type p53 allele.
However, in choroid plexus of tumors of these patients,
normal p53 was maintained but SV40 DNA sequences and
T-Ag were detected. It has been suggested that p53 hap-
loinsufficiency of individuals with Li Fraumeni syndrome
predisposes them to develop SV40-associated in susceptible
tissues such as the choroid plexus (Garcea and Imperiale,
2003). Indirect evidence for a link between SV40 and
cancers comes from the observations that mesotheliomas
from Finland and Turkey (where polio vaccine was not
administered) are negative for SV40 (Hirvonen et al., 1999;
Emri et al., 2000). Direct evidence for SV40 was provided
by Lednicky et al. (1995) who reported the isolation of
infectious SV40 from a sample of choroid plexus tumor
tissue after lipofection of tumor DNA into monkey kidney
cells. Waheed et al. (1999) have demonstrated that an
adenoviral vector expressing antisense transcript to SV40
early region induced growth arrest and apoptosis in SV40-
positive human mesothelioma cells growing in culture.
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scientist who had a risk of laboratory exposure to SV40.
SV40 DNA was isolated from the tumor and cerebrospinal
fluid of the patient and was found to have had an identical
sequence to the laboratory source. It would be of interest to
examine cancer samples from other individuals with prior
occupational exposure to SV40. Thus, the evidence for the
association of SV40 with human cancer continues to
strengthen and should no longer be dismissed on the
grounds of the technical issues regarding PCR and antibody
specificity.
Is the association of SV40 with human tumors causal or
incidental? Does SV40 initiate tumorigenic events or do
tumors offer a microenvironment that favors viral replica-
tion in humans with latent SV40 infection? SV40 has a very
potent oncogene, T-Ag, and is highly tumorigenic in cell
cultures and animals so it would be surprising if SV40 were
associated with tumors merely by chance. However, there
still remains a lack of clear epidemiological evidence. The
Institute of Medicine (IOM) recently reviewed the evidence
associating polio vaccines and SV40 with human tumors
and concluded that the epidemiological studies are suffi-
ciently flawed that the evidence was inadequate to conclude
whether or not contaminated polio vaccine caused cancer
(IOM report, 2002). The IOM report also acknowledged that
the biological effects of SV40 were consistent with its being
a tumor virus.Conclusions
Three polyomaviruses have been discussed that are
thought to have a possible role in the etiology of human
malignancies. Studies on the molecular biology of these
viruses and their effects on cultured cells and in animal
models form a coherent picture with what is know about
these viruses and their associations in a clinical setting.
However, it remains to be stringently proven that they have
a causal role in human neoplasia. Problems include the
following: The viruses are ubiquitous in nature but the
associated cancer is rare. The incubation period between
infection and appearance of cancer is long. The initial viral
infection is usually subclinical making it difficult to estab-
lish when it occurred. The human viruses JCV and BKV do
not productively infect animal models. Environmental
cofactors (e.g., cocarcinogens) or host factors (e.g., immune
status) modulate pathogenesis. These considerations make it
difficult to apply Koch’s postulates to the polyomaviruses.
Zur Hausen has proposed alternative criteria for defining a
causal role for an infection in cancer (zur Hausen, 1999): (1)
epidemiological plausibility and evidence that a virus infec-
tion represents a risk factor for the development of a specific
tumor; (2) regular presence and persistence of the nucleic
acid of the respective agent in cells of the specific tumor; (3)
stimulation of cell proliferation upon transfection of the
respective genome or parts therefrom in correspondingtissue culture cells; (4) demonstration that the induction of
proliferation and the malignant phenotype of specific tumor
cells depend on functions exerted by the persisting nucleic
acid of the respective agent.
Evidence has been presented here that the JCV, BKV, and
SV40 polyomaviruses fulfill at least the last three criteria.
These viruses transform cells in culture and produce tumors
in inoculated animals or transgenic mice with patterns con-
sistent with their putative role in human tumorigenesis, as we
have described. The presence of viral DNA and viral gene
expression in a subset of human tumors has been established.
The differences between the polyomaviruses can be
ascribed, at lease in part, to divergences in viral tropisms
with respect to cells in culture, laboratory animals, and
human cancers. As we have described, the important deter-
minant of tropism is the noncoding regulatory region.
Whether differences in functions between the transforming
proteins of the polyomaviruses are important is still not fully
resolved. However, in the cases where functions have been
compared between polyomaviruses, conservation of func-
tion was always found (Table 1). Taken together with the
high degree of sequence conservation of the polyomavirus
transforming proteins (Table 2), it seems likely that they all
operate by the same mechanisms.
Future studies of polyomaviruses will be aided by recent
technical advances. Oligonucleotide-based microarray
approaches should permit the evaluation of the expression
of many thousands of genes at once to generate transcrip-
tional profiles that can be used to examine the effects of
polyomaviruses in cell culture systems and in tumors.
Radhakrishnan et al. (2003) correlated changes in gene
expression in primary human astrocytes after JCV infection
with gene expression alterations that were observed in
astrocytes within PML lesions of brain tissue from patients
with neuro-AIDS. Proteomics-based approaches could be
used to assess the status of T-Ag in tumors. For example,
two-dimensional electrophoresis could be used to resolve T-
Ag/p53 followed by mass spectrometry to evaluate the
identity of the T-Ag protein (JCV, BKV, or SV40) and the
status of the p53 protein (wild-type or mutated).
Rather than to focus on a debate over whether polyoma-
viruses ‘‘cause cancer’’, it might be better to view the viral
oncoproteins as putative targets for therapeutic intervention.
Treatment of a particular cancer, whether by gene therapy or
by small molecule inhibitors, is predicated upon a knowl-
edge of the signal transduction pathways that have become
dysregulated within the tumor. Usually, cancer is thought of
as a disease that progresses through the gradual accumula-
tion of multiple successive genetic ‘‘hits’’ leading from
normal cells to fully malignant metastatic tumors (Fearon
and Vogelstein, 1990). These hits include activation of
oncogenes, knockout of tumor suppressors, and events that
increase mutation rates or destabilize the genome. Each hit
represents a target for strategies designed to reverse malig-
nancy. Activation of expression of latent polyomavirus may
represent such a hit. The highly multifunctional polyoma-
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transduction pathways (Table 1) and thus molecular strate-
gies for the disruption of their interactions with cellular
proteins may represent a fruitful avenue for the development
of new types of therapeutic interventions. For example,
ELISA-based assays for T-Ag/p53 interaction have been
used to screen chemical libraries for agents that inhibit T-Ag
binding to p53 (Carbone et al., 2003a, 2003b). Delivery of
antisense transcripts to the early region of SV40 using an
adenoviral gene therapy vector achieved significant growth
inhibition and apoptosis of T-antigen-expressing human
mesothelioma cells in culture (Waheed et al., 1999).
Agents that target the polyomavirus proteins have the
potential of providing new therapies for certain cancers and
of answering questions about the importance of polyoma-
virus protein functions in neoplasia.Acknowledgments
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